Bilateral injection of rAAV1 or rAAV2-insulin-like growth factor 1 (Igf-1) into DCN results in IGF expression throughout the cerebellar cortex, hindbrain, brain stem, and spinal cord, and it delays the progression of the amyotrophic lateral sclerosis (ALS) mouse model, providing a novel gene therapy delivery route for ALS (Dodge et al., 2008). The gene discussed is IGF1; the disease is amyotrophic lateral sclerosis.